Medical University of South Carolina, SC College of Pharmacy, Department of Clinical Pharmacy and Outcome Sciences, 280 Calhoun Street, Charleston, SC 29425, USA.
Expert Opin Pharmacother. 2011 Jan;12(1):99-117. doi: 10.1517/14656566.2010.516747. Epub 2010 Nov 26.
Statins are widely accepted as the drugs of choice for achieving increasingly stringent low-density lipoprotein cholesterol (LDL-C) goals for dyslipidemic patients. However, when making treatment decisions, outcomes data from clinical trials are of greater importance than LDL-C-lowering ability.
This review will provide an update on current lipid treatment guidelines in the context of statin trial evidence, with particular focus on the incremental benefit of more potent statin therapy compared with lower doses. The discussion will also address combination therapy, statin safety, goal attainment and treatment adherence. MEDLINE searches (1966 to July 2010) were performed.
The reader will gain a comprehensive review of the evidence base for statin therapy and an appreciation of other issues that affect treatment choice.
It is important to remember why we need to partner with our patients: to ensure that they are established on, and continue to adhere to, their appropriate evidence-based statin dose with a goal of achieving lipid targets, but more importantly to prevent cardiovascular disease-related morbidity and mortality. We treat patients to reduce clinical cardiovascular events, not just to control lipids and other important risk factors.
他汀类药物被广泛认为是实现血脂异常患者日益严格的低密度脂蛋白胆固醇（LDL-C）目标的首选药物。然而，在做出治疗决策时，临床试验的结果数据比降低 LDL-C 的能力更为重要。
本综述将根据他汀类药物试验证据，提供当前脂质治疗指南的最新信息，特别关注与低剂量相比，更有效的他汀类药物治疗的增量效益。讨论还将涉及联合治疗、他汀类药物安全性、目标达标和治疗依从性。
检索了 MEDLINE（1966 年至 2010 年 7 月）。
读者将全面了解他汀类药物治疗的证据基础，并了解影响治疗选择的其他问题。
与患者合作非常重要：确保他们开始并继续坚持适当的、基于证据的他汀类药物剂量，以实现血脂目标，但更重要的是预防与心血管疾病相关的发病率和死亡率。我们治疗患者是为了减少临床心血管事件，而不仅仅是控制血脂和其他重要的危险因素。
